Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and…

CARLSBAD, Calif.--(BUSINESS WIRE)--Accelerated Biosciences, a regenerative medicine innovator, announced today new data that further demonstrates statistically significant cytolysis with induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells programmed from its ethically sourced human trophoblast stem cells (hTSCs). Pluristyx, a Seattle-based firm supporting drug development, regenerative medicine, and cell and gene therapies, further confirmed Accelerated Biosciences hTSC line offers before-unrealized opportunities in cell-specific therapeutics. Along with this recent data on successful iPSC differentiation, Accelerated Biosciences has already demonstrated efficient differentiation of its pluripotent stem cells with remarkable doubling times and growth characteristics to programmed NK, cartilage, bone, fat, neuron, pancreas, liver, and secretome cells.

This new data validates our findings, explains Yuta Lee, President and Founder of Accelerated Biosciences. We know the properties of our trophoblast stem cells have been long-sought by the medical science community because of the potential to speed and amplify the development of life-saving therapeutics; theyre immune privileged, chromosomally stable (not tumorigenic), pathogen free, pluripotent, easy to scale and manufacturer, and of special interest, they are ethically sourced from the chorionic villi (pre-placental tissue) of non-viable and often life-threatening tubal ectopic pregnancies. Mr. Lees father, Professor Jau-Nan Lee, MB, MD, PhD, an obstetrics and gynecologic physician and researcher in Taiwan, first isolated hTSC in 2003. Mr. Lee created Accelerated Biosciences to elevate the visibility of this pluripotent human trophoblast stem cell platform to those engaged in developing allogeneic cell therapeutics and has been instrumental in the filing and prosecution of intellectual property to protect the companys hTSC platform to date holding 34 patents.

Benjamin Fryer, PhD, Co-founder and CEO of Pluristyx, worked closely with Accelerated Biosciences to prepare much of its key hTSC data. Dr. Fryer, a trophoblast expert who was previously a research scientist at Janssen Research & Development of Johnson & Johnson, now serves on Accelerated Biosciences Scientific Advisory Board. Initially I was skeptical these cells were what they said they were. If we hadnt grown and characterized them in our lab, I might have remained skeptical. These are indeed trophoblast stem cells, explained Dr. Fryer. The potential of these cells is enormous. One of the industrys largest challenges is that its almost impossible to scale primary cells. These cells are scalable. With these cells you can make the amount required for millions of patients and theyre sourced compliant to regulatory requirements. Weve made IPS cells (induced pluripotent stem cells) and NK (natural killer) cells from them, which is the next wave of cells for cell therapies. For therapeutic developers, because these cells are not sourced from a person or viable embryo, these cells deliver the trifecta of legal, ethical, and IP advantages.

As the biotechnology industry works toward developing therapies that target only diseased cells without harming healthy cells and tissues, cell-based therapies draw increasing interest, explains industry expert, Martina Molsbergen, CEO of C14 Consulting, who has partnered with Accelerated Biosciences in a business development role. With all the promise that cell therapies hold, the biotechnology industry also remains concerned that the therapeutics are derived in a socially and ethically responsible manner. Accelerated Biosciences has discovered and is now offering what scientists see as the holy grail of stem cell sources.

Prominent biosciences experts have been drawn to Accelerated Biosciences cell breakthrough. Protein chemist and molecular biologist Igor Fisch, PhD, former President and CEO of Selexis, Geneva, Switzerland, recognizes the impact that Accelerated Biosciences hTSCs will have on human health: Not only are these cells politically correct, but they can also differentiate. Because they are sourced from pre-placenta material, theyre immune privileged, which means that are not seen as foreign by the human body. With these cells, we can create a cell bank a single source for a wide range of patients.

Peter Hudson, FTSE, BSc Hons, PhD, Chief Scientist and a senior advisor to Avipep P/L in Melbourne, Australia, and an adjunct professor at the University of Queensland, led a large oncology consortium to complete the first Phase 1 clinical trial of a novel engineered antibody targeting prostate and ovarian cancer. Hudsons interest in Accelerated Biosciences hTSCs has evolved into a role on its Scientific Advisory Board. Trophoblast stem cells are likely to be the next wave of cancer-targeting therapeutics, explains Dr. Hudson. The ability to ethically source trophoblast stem cells and program them to target only diseased, cancerous cells is very powerful technology.

Why are scientists so interested in stem cell-based therapies?

The human body constantly produces specialized cells from its own stem cells (undifferentiated cells) to renew and repair itself. Current therapies harness this power in autologous cell therapies in which the patients own cells are removed, differentiated into disease-fighting cells, and reinserted.

What makes the human trophoblast stem cell so important to medical science?

The human trophoblast stem cell (hTSC) comes from placental tissue and has special properties that make it extremely desirable to therapeutic developers. The hTSC is such an early stem cell that it has much more capacity for growth than a stem cell taken from an adult, for example. This means that one cell can become millions. The hTSC also carries with it the same immune-privilege that a growing embryo has inside its mother: its not seen as foreign although its genetically different than its mother. Unlike other foreign materials, the hTSC is not rejected by the human body, which means that it can be used with many different patients (allogeneic cell therapy). With these benefits, the scientific community holds a high regard for hTSCs, but it also faces socio-ethical concerns about how those stem cells are typically sourced.

Accelerated Biosciences sidesteps hTSC sourcing concerns in a profoundly elegant way. Dr. Jau-Nan Lee, an OB-GYN in Taiwan, found inspiration in what was considered medical waste. When surgical intervention was necessary to remove an ectopic pregnancy that would otherwise risk the womans life, the non-viable embryo and pre-placental tissue lodged in the fallopian tube was removed, sent to pathology, and discarded. Gaining permission from institutional colleagues and sampling the pre-placental tissue, Dr. Lee isolated hTSC that offered all the benefits of hTSC pluripotency, immune privilege, and scalability without pathogens and without ethical compromises.

About Accelerated Biosciences

Founded in 2013, Accelerated Biosciences is a private company focused on regenerative medicine and built around the hTSC discoveries of obstetrics and gynecology physician and researcher, Professor Jau-Nan Lee, MB, MD, PhD. Accelerated Biosciences holds a large and robust patent portfolio and an encumbrance-free intellectual property (IP) estate. Accelerated Biosciences mission is to leverage its renewable, immune-privileged human cell source to fuel breakthrough cell therapies that effectively target the most challenging diseases of the human body. For more information about Accelerated Biosciences, visit acceleratedbio.com or email mmolsbergen@c14consultinggroup.com.

Read the rest here:

Accelerated Biosciences' Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and...

Read more
The Induced Pluripotent Stem Cells Market To Witness A Spike Amidst Entry Of New Players – Industry Today

Artificial Intelligence is the future of the healthcare industry. This could be attributed to improvements in diagnostic precision as there would be automatic assistance regarding clinical operation, workforce, and quantitative imaging. The Induced Pluripotent Stem Cells Market report by Persistence Market Research emphasizes on the inflow of artificial intelligence therein and also the medications (pharmaceuticals) to be rendered. Precise diagnostics leads to precise rendition of drugs.

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/17968

Company Profile

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/17968

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition.

This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation.

A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strongCAGR of 7.0%from 2018 to 2026. In 2017, the market was worthUS$ 1,254.0 Mnand is expected to reachUS$ 2,299.5 Mnby the end of the forecast period in 2026.

Access Full Report @https://www.persistencemarketresearch.com/checkout/17968

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Top Reports of Persistence Market Research :-

Active Pharmaceutical Ingredient Market Persistence Market Research predicts that the globalactive pharmaceutical ingredients marketto exhibit a CAGR above 4% over the forecast period (2021-2031).

Opioids MarketAccording to the revised report published by Persistence Market Research, the globalopioids marketvalued at US$ 40.5 Bn in 2020, and is predicted to expand at a CAGR of 3% over the forecast period (20212031).

Autogenous Vaccines MarketAccording to a revised report published by Persistence Market Research, theautogenous vaccines marketwas valued over US$ 116 Mn in 2020, and is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031).

About us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact us:

Persistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsite https://www.persistencemarketresearch.com

See the rest here:

The Induced Pluripotent Stem Cells Market To Witness A Spike Amidst Entry Of New Players - Industry Today

Read more
Induced Pluripotent Stem Cells (iPSCs) Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Fujifilm Holding Corporation (CDI),…

Industry Growth Insights (IGI) recently published a latest research study on the global Induced Pluripotent Stem Cells (iPSCs) market for the forecast period, 2021-2028. As per the study, the global Induced Pluripotent Stem Cells (iPSCs) market was valued at USDXX million and is projected to surpass USDXX million by the end of 2027, expanding at a CAGR of XX% during the forecast period. This research report offers a comprehensive outlook of the market with detailed information about drivers, restraints, opportunities, trends, and challenges, which are the key factors that can influence the market outcome in the targeted years.

The market report offers a concise overview of the segments and sub-segments including the product types, applications, players, and regions to provide the key aspects of the market. The report focuses on the COVID-19 pandemic and its impact on the current market and provides an in-depth explanation about the market situation in the coming years. The report thoroughly studies the market dynamics, changing consumer behavior, and the flow of the global supply chain of the market, impacted by the ongoing pandemic. These critical insights of the report aim to present a robust guideline for the clients to arrive an informed business decision about their investment in the market since it evaluates the factors that are likely to influence the current and future market situation.

The global Induced Pluripotent Stem Cells (iPSCs) market includes

Fujifilm Holding Corporation (CDI)NcardiaSumitomo Dainippon PharmaAstellas Pharma IncFate Therapeutics, IncPluricell BiotechCell Inspire BiotechnologyReproCELLInduced Pluripotent Stem Cells (iPSCs

** Additional companies can be provided at the request of clients.

Get Exclusive Free Sample Report: https://industrygrowthinsights.com/request-sample/?reportId=171605

Segmentation Insight

The report offers an in-depth analysis of segments and sub-segments of the Induced Pluripotent Stem Cells (iPSCs) market. It provides a broad outlook regarding the performance, market valuation, and growth opportunities of each segment along with the expected CAGR including various sub-segments of each segment during the forecast period. Moreover, the segment part includes both drivers and restraining factors to explain the potential expansion of the market. The report covers the major industries that extensively use the product for their various applications. A detailed explanation is provided in the report about the areas of applications describing where the product is adopted by key industries to leverage their business portfolio.

The global Induced Pluripotent Stem Cells (iPSCs) market is segmented into

By Types/Product

Human iPSCsMouse iPSCsHuman iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.Induced Pluripotent Stem Cells (iPSCs

By Applications/End-Users

Academic ResearchDrug Development and DiscoveryToxicity ScreeningRegenerative Medicine

Buy The Complete Report: https://industrygrowthinsights.com/checkout/?reportId=171605

Regional Markets

The report conducts a compressive study about potential growth opportunities, revenue share, and major challenges of five major regions namely Asia Pacific, Europe, North America, Latin America, and Middle East & Africa (MEA) of Induced Pluripotent Stem Cells (iPSCs) market. A wide range of information is included in the report about the performance and potential market destination in sub-regions and countries within a region. North America includes countries such as the U.S., and Canada. Europe as a region is further categorized as the U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is classified as China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America as a region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region includes GCC, Turkey, South Africa, and Rest of MEA.

Additionally, the COVID-19 pandemic and its impacts on these regional markets comprises a major part of the chapter to understand a broad picture of the overall market development. Meanwhile, this report can be customized and available for any specific region as per the need of the clients.

Competitive Landscape

The report covers key players of the Induced Pluripotent Stem Cells (iPSCs) market and their market position as well as performance over the years. It offers a detailed insight about the latest business strategies such as mergers, partnerships, product launch, acquisitions, expansion of production units, and collaborations, adopted by some major global players. In this chapter, the report explains about the key investment on R&D activities from key players to help expand their existing business operations and geographical reach. Additionally, the report evaluates the scope of growth and market opportunities of new entrants or players in the market.

For Any Question Regarding This Report: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=171605

Reasons to buy this report

This report offers a broad and concise analysis of the Induced Pluripotent Stem Cells (iPSCs) market using a robust research methodology and focusing on various data available for the historical period of past two years. It also covers some key segments and potential regional market in details that are expected to boost the overall market significantly during the forecast period. Moreover, this report is prepared with an objective to ease the understanding of contents as it provides a range of concise graphical representations, tables, and figures.

Additionally, the report answers some of these main questions of the market:

Major Points Covered In This Report:

Chapter 1. Report Overview

Chapter 2. Global Growth Trends

Chapter 3. Market Share by Key Players

Chapter 4. Breakdown Data by Type and Application

Chapter 5. Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Induced Pluripotent Stem Cells (iPSCs) Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Force

And Many More

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 414 1393Email: [emailprotected]Website: https://industrygrowthinsights.com

https://neighborwebsj.com/

Excerpt from:

Induced Pluripotent Stem Cells (iPSCs) Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Fujifilm Holding Corporation (CDI),...

Read more
Induced Pluripotent Stem Cells (iPSCs) Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players…

Industry Growth Insights (IGI) has added a latest report on the Global Induced Pluripotent Stem Cells (iPSCs) Market that covers the 360 scope of the market and various parameters that are speculated to proliferate the growth of the market during the forecast period, 2021-2028. The market research report provides in-depth analysis in a structured and concise manner, which in turn, is expected to help the esteemed reader to understand the market exhaustively.

Major Players Covered In This Report:

Fujifilm Holding Corporation (CDI)NcardiaSumitomo Dainippon PharmaAstellas Pharma IncFate Therapeutics, IncPluricell BiotechCell Inspire BiotechnologyReproCELLInduced Pluripotent Stem Cells (iPSCs

The research report confers information about latest and emerging market trends, key market drivers, restraints, and opportunities, supply & demand scenario, and potential future market developments that are estimated to change the future of the market. This report also serves the strategic market analysis, latest product developments, comprehensive analysis of regions, and competitive landscape of the market. Additionally, it discusses top-winning strategies that has helped industry players to expand their market share.

Get Exclusive Sample Report for Free @ https://industrygrowthinsights.com/request-sample/?reportId=171605

9 Key Report Highlights

Historical, Current, and Future Market Size and CAGR

Future Product Development Prospects

In-depth Analysis on Product Offerings

Product Pricing Factors & Trends

Import/Export Product Consumption

Impact of COVID-19 Pandemic

Changing Market Dynamics

Market Growth in Terms of Revenue Generation

Promising Market Segments

Impact of COVID-19 Pandemic On Induced Pluripotent Stem Cells (iPSCs) Market

The COVID-19 pandemic had persuaded state government bodies to impose stringent regulations on the opening of manufacturing facilities, corporate facilities, and public places. It had also imposed restrictions on travelling through all means. This led to the disruption in the global economy, which negatively impacted the businesses across the globe. However, the key players in the Induced Pluripotent Stem Cells (iPSCs) market created strategies to sustain the pandemic. Moreover, some of them created lucrative opportunities, which helped them to leverage their market position.

The dedicated team at Industry Growth Insights (IGI) closely monitored the market from the beginning of the pandemic. They conducted several interviews with industry experts and key management of the top companies to understand the future of the market amidst the trying times. The market research report includes strategies, challenges & threats, and new market avenues that companies implemented, faced, and discovered respectively in the pandemic.

On What Basis the Market Is Segmented in The Report?

The global Induced Pluripotent Stem Cells (iPSCs) market is fragmented on the basis of:

Products

Human iPSCsMouse iPSCsHuman iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.Induced Pluripotent Stem Cells (iPSCs

The drivers, restraints, and opportunities of the product segment are covered in the report. Product developments since 2017, products market share, CAGR, and profit margins are also included in this report. This segment confers information about the raw materials used for the manufacturing. Moreover, it includes potential product developments.

Applications

Academic ResearchDrug Development and DiscoveryToxicity ScreeningRegenerative Medicine

The market share of each application segment is included in this section. It provides information about the key drivers, restraints, and opportunities of the application segment. Furthermore, it confers details about the potential application of the products in the foreseeable future.

Regions

North America

Asia Pacific

Europe

Latin America

Middle East & Africa

Note: A country of choice can be included in the report. If more than one country needs to be added in the list, the research quote will vary accordingly.

The market research report provides in-depth analysis of the regional market growth to determine the potential worth of investment & opportunities in the coming years. This Induced Pluripotent Stem Cells (iPSCs) report is prepared after considering the social and economic factors of the country, while it has also included government regulations that can impact the market growth in the country/region. Moreover, it has served information on import & export analysis, trade regulations, and opportunities of new entrants in domestic market.

Buy the complete report @ https://industrygrowthinsights.com/checkout/?reportId=171605

7 Reasons to Buy This Report

Usage of Porters Five Force Analysis Model

Implementation of Robust Methodology

Inclusion of Verifiable Data from Respectable Sources

Market Report Can Be Customized

Quarterly Updates On Market Developments

Presence of Infographics, Flowcharts, And Graphs

Provides In-Depth Actionable Insights to Make Crucial Decisions

Ask for discount @ https://industrygrowthinsights.com/ask-for-discount/?reportId=171605

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Induced Pluripotent Stem Cells (iPSCs) Market Overview

Global Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast by Type

Global Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast by Application

Global Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast by Sales Channel

Global Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast by Region

North America Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast

Latin America Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast

Europe Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast

Asia Pacific Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast

Asia Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Application

Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast

Competition Landscape

If you have any doubt regarding the report, please connect with our analyst @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=171605

About Industry Growth Insights (IGI)

Industry Growth Insights (IGI) has extensive experience in the creation of tailored market research reports in several industry verticals. We cover in-depth market analysis which includes producing creative business strategies for the new entrants and the emerging players of the market. We take care that our every report goes through intensive primary, secondary research, interviews, and consumer surveys. Our company provides market threat analysis, market opportunity analysis, and deep insights into the current and market scenario.

To provide the utmost quality of the report, we invest in analysts that hold stellar experience in the business domain and have excellent analytical and communication skills. Our dedicated team goes through quarterly training which helps them to acknowledge the latest industry practices and to serve the clients with the foremost consumer experience.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 414 1393Email: [emailprotected]Website: https://industrygrowthinsights.com

See more here:

Induced Pluripotent Stem Cells (iPSCs) Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players...

Read more
Global Induced Pluripotent Stem Cells Market Analysis By Future Demand, Top Players, Industry Share Size, Revenue and Growth Rate Through…

Databridgemarketresearch.com Present Global Induced Pluripotent Stem Cells Market Industry Trends and Forecast to 2027 new report to its research database. The report spread No of pages : 350 No of Figures: 60 No of Tables: 220 in it.

Induced pluripotent stem cells (iPSCs) marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 2,442.97 million by 2027 growing at a CAGR of 7.5% in the above-mentioned forecast period. Increasing R&D investment activities is expected to create new opportunity for the market.

Induced pluripotent stem cells market report helps businesses to look for a better solution to refine their business strategies with which they can succeed in this competitive market place. This report underlines the moves of key market players like product launches, joint ventures, developments, mergers and acquisitions which is affecting the market and healthcare Industry as a whole and also affecting the sales, import, export, revenue and CAGR values. All the statistical and numerical data that has been forecasted in the winning Induced pluripotent stem cells report is represented with the help of graphs, charts, or tables which makes this report more user friendly.

Get Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-induced-pluripotent-stem-cells-market

Few of the major competitors currently working in global induced pluripotent stem cells market areFUJIFILM Holdings Corporation, Astellas Pharma Inc, Fate Therapeutics, Bristol-Myers Squibb Company, ViaCyte, Inc., CELGENE CORPORATION, Vericel Corporation, KCI Licensing, Inc, STEMCELL Technologies Inc., Japan Tissue Engineering Co., Ltd., Organogenesis Holdings Inc, Lonza, Takara Bio Inc., Horizon Discovery Group plc, Thermo Fisher Scientific.

Study Objectives Of Induced pluripotent stem cells Market

Global Induced Pluripotent Stem Cells (iPSCs) Market Scope and Market Size

Induced pluripotent stem cells (iPSCs) market is segmented of the basis of derived cell type, application and end- user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-induced-pluripotent-stem-cells-market

Global Induced Pluripotent Stem Cells Market Drivers:

Increasing R&D investment activities is expected to create new opportunity for the market.

Increasing demand for personalized regenerative cell therapies among medical researchers & healthcare is expected to enhance the market growth. Some of the other factors such as increasing cases of chronic diseases, growing awareness among patient, rising funding by government & private sectors and rising number ofclinical trialsis expected to drive the induced pluripotent stem cells (iPSCs) market in the forecast period of 2020 to 2027.

High cost of the induced pluripotent stem cells (iPSCs) and increasing ethical issues & lengthy processes is expected to hamper the market growth in the mentioned forecast period.

Key Developments in the Market:

TOC of Induced Pluripotent Stem Cells Market Report Contains:

Get Full Table Of content @https://www.databridgemarketresearch.com/toc/?dbmr=global-induced-pluripotent-stem-cells-market

Report points with potential

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:Corporatesales@databridgemarketresearch.com

Read more:

Global Induced Pluripotent Stem Cells Market Analysis By Future Demand, Top Players, Industry Share Size, Revenue and Growth Rate Through...

Read more
Global Stem Cell Therapy Market 2020-2027 Trends, industry vertical, along with the geography, delivering valuable insights | Reportspedia Clark…

The Global Stem Cell Therapy Market Report is a complete and unique study of Stem Cell Therapys landscape structure. Initially, it gives us an overview of global market size and forecast, market characteristics, global and regional market size, market growth of Stem Cell Therapy market, production data, imports and exports statistics of Stem Cell Therapy industry are detailed in this study which is segmented by type, application, and consumption area of Stem Cell Therapy.

Find out how COVID-19 has affected the growth of the industry. Get a free sample report with detailed analysis @

https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#request-sample

This comprehensive report elaborates on the global Stem Cell Therapy market value growth trend from 2020 to 2027. This study is a fragmentary description of the Stem Cell Therapy structure to provide a complete consumer perspective and a complete analysis of the Stem Cell Therapy industry.

The next section or segment of the report provides a comprehensive analysis including information such as a detailed explanation of the product structure, the economic background of the market, dynamics of supply and demand, trade statistics, and product value analysis are analyzed in this report. The key development strategies plans and policies for the Stem Cell Therapy market are examined about their impact on the market in the forecast period.

The research report evaluates detailed historical data on product volume, capacity, demand, and supply chain logistics in the product market to assess the markets acute impact of the COVID-19 and pandemic epidemics. It analyzes the evolution of trends and considers recent developments that are likely to have an impact on market conditions in the coming period.

Do Inquiry Before Buying https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#inquiry_before_buying

This report is segmented into 3 segments i.e by type, application, and region

Based on type and applications this study presents vital information like market value, market share, growth rate, buyers, and consumption of Stem Cell Therapy from 2015-2020.

Market Segmentation:

Major Types covered,

Adult Stem CellsHuman EmbryonicInduced Pluripotent Stem CellsVery Small Embryonic Like Stem Cells

Major Applications covered,

Regenerative MedicineDrug Discovery and Development

Regions Covered in this research:

Regional Analysis

Download a free sample report with all tables and graphs

https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#request-sample

Under the segment industry chain structure, users will get information on upstream raw material suppliers of Stem Cell Therapy. Major players of Stem Cell Therapy, their market share, manufacturing base are also covered. The cost structure analysis explains the cost of raw materials involved in Stem Cell Therapy and labor cost. The marketing channels and downstream buyers of Stem Cell Therapy are described in this study.

The report answers some important questions:

Browse Full TOC, [emailprotected] https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#table-of-contents

Go here to read the rest:

Global Stem Cell Therapy Market 2020-2027 Trends, industry vertical, along with the geography, delivering valuable insights | Reportspedia Clark...

Read more
Synthego Launches Eclipse Platform to Accelerate Research and Development of Next-generation Medicines – The Scientist

Synthego, the genome engineering company, today announced the launch of Eclipse, a new high-throughput cell engineering platform designed to accelerate drug discovery and validation by providing highly predictable CRISPR-engineered cells at scale through the integration of engineering, bioinformatics, and proprietary science. The launch of this unique CRISPR-based platform is driving the companys growing impact in biopharma R&D, reinforcing Synthegos position as the genome engineering leader.

CRISPR-engineered cells have a wide range of applications in research and development across disease areas, including in neuroscience and oncology. Synthego created the Eclipse Platform to enhance disease modeling, drug target identification and validation, and accelerate cell therapy manufacturing.

"By industrializing cell engineering, Synthegos Eclipse Platform will enable economies of scale, turning a historically complex process into one that is flexible, reliable, and affordable, said Bill Skarnes, Ph.D., professor and director of Cellular Engineering at The Jackson Laboratory and Synthego advisory board member. Offering CRISPR edits at scale, similar to what Synthego did with sgRNA reagents, puts researchers on the cusp of being able to study thousands of genes, and examine hundreds of variants of those genes. This will allow scientists to more faithfully model the complexity of a human disease, which could lead to the development of therapeutic drugs or next-generation gene therapies for many serious diseases.

To ensure the success of any type of edit, Eclipse uses machine learning to apply experience from several hundred thousand genome edits across hundreds of cell types. With this machine learning, combined with automation, the new platform can reduce costs and increase the scalability of engineered cell production. The Eclipse Platform is modular in design, allowing for fast deployment of upgrades or add-ons. It is engineered to use a cell-type agnostic process and immediately benefit researchers working with induced pluripotent stem (iPS) cells and immortalized cell lines.

We are living in a new era of life sciences innovation one that has added to DNA sequencing and being able to read out of biology, now being able to write into and engineer biology. We created our Eclipse Platform at the convergence of science and technology to make genome editing more precise, scalable, and accessible, said Paul Dabrowski, CEO and co-founder of Synthego. We are excited to expand our impact on advancing the life sciences innovation with the launch of this unique CRISPR-based platform.

Read more here:

Synthego Launches Eclipse Platform to Accelerate Research and Development of Next-generation Medicines - The Scientist

Read more
Global Induced Pluripotent Stem Cell (iPS Cell) Market Report 2021: In Total, At Least 68 Distinct Market Competitors Now Offer Various Types of iPSC…

DUBLIN, April 15, 2021 /PRNewswire/ -- The "Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021" report has been added to ResearchAndMarkets.com's offering.

The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics.

Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.

Therapeutic applications of iPSCs have surged in recent years. 2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB), it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration.

In another world-first, Cynata Therapeutics received approval in 2016 to launch the world's first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD.

Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its "off-the-shelf" iPSC-derived CAR-T cell product candidate. Numerous physician-led studies using iPSCs are also underway in Japan, a leading country for basic and applied iPSC applications.

iPS Cell Market Competitors

Today, FUJIFILM CDI has emerged as one of the largest commercial players within the iPSC sector. FUJIFILM CDI was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time ever. The feat was accomplished simultaneously by Dr. Shinya Yamanaka's lab in Japan.

In 2009, ReproCELL, a company established as a venture company originating from the University of Tokyo and Kyoto University, made iPSC products commercially available for the first time with the launch of its human iPSC-derived cardiomyocytes, which it called ReproCario.

A European leader within the iPSC market is Ncardia, formed through the merger of Axiogenesis and Pluriomics. Founded in 2001, Axiogenesis initially focused on generating mouse embryonic stem cell-derived cells and assays, but after Yamanaka's iPSC technology became available, it became the first European company to license it in 2010. Ncardia's focus is on preclinical drug discovery and drug safety through the development of functional assays using human neuronal and cardiac cells.

In total, at least 68 distinct market competitors now offer various types of iPSC products, services, technologies and therapies.

iPS Cell Commercialization

Methods of commercializing induced pluripotent stem cells (iPSCs) are diverse and continue to expand. iPSC cell applications include, but are not limited to:

Since the discovery of iPSC technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated.

Key Topics Covered:

1. REPORT OVERVIEW1.1 Statement of the Report1.2 Executive Summary

2. INTRODUCTION2.1 Discovery of iPSCs2.2 Barriers in iPSC Application2.3 Timeline and Cost of iPSC Development2.4 Current Status of iPSCs Industry2.4.1 Share of iPSC-based Research within the Overall Stem Cell Industry2.4.2 Major Focuses of iPSC Companies2.4.3 Commercially Available iPSC-Derived Cell Types2.4.4 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays2.4.5 Toxicology/Safety Testing Assays using iPSC-Derived Cell Types2.5 Currently Available iPSC Technologies2.6 Advantages and Limitations of iPSCs Technology

3. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)3.1 First iPSC generation from Mouse Fibroblasts, 20063.2 First Human iPSC Generation, 20073.3 Creation of CiRA, 20103.4 First High-Throughput screening using iPSCs, 20123.5 First iPSCs Clinical Trial Approved in Japan, 20133.6 The First iPSC-RPE Cell Sheet Transplantation for AMD, 20143.7 EBiSC Founded, 20143.8 First Clinical Trial using Allogeneic iPSCs for AMD, 20173.9 Clinical Trials for Parkinson's disease using Allogeneic iPSCs, 20183.10 Commercial iPSC Plant SMaRT Established, 20183.11 First iPSC Therapy Center in Japan, 2019

4. RESEARCH PUBLICATIONS ON iPSCS4.1 Categories of Research Publications4.2 Percent Share of Published Articles by Disease Type4.3 Number of Articles by Country

5. IPSCS: PATENT LANDSCAPE5.1 Timeline and Status of Patents5.2 Patent Filing Destinations5.2.1 Patent Applicant's Origin5.2.2 Top Ten Global Patent Applicants5.2.3 Collaborating Applicants of Patents5.3 Patent Application Trends iPSC Preparation Technologies5.4 Patent Application Trends in iPSC Differentiation Technologies5.5 Patent Application Trends in Disease-Specific Cell Technologies

6. CLINICAL TRIALS INVOLVING iPSCS6.1 Current Clinical Trials Landscape6.1.1 Clinical Trials Involving iPSCs by Major Diseases6.1.2 Clinical Trials Involving iPSCs by Country

7. FUNDING FOR iPSCs7.1 Value of NIH Funding for iPSCs7.1.1 NHI's Intended Funding Through its Component Organizations in 20207.1.2 NIH Funding for Select Universities for iPSC Studies7.2 CIRM Funding for iPSCs

8. GENERATION OF INDUCED PLURIPOTENT STEM CELLS: AN OVERVIEW8.1 Reprogramming Factors8.2 Overview of Four Key Methods of Gene Delivery8.3 Comparative Effectiveness of Different Vector Types8.4 Genome Editing Technologies in iPSCs Generation

9. HUMAN iPSC BANKING9.1 Cell Sources for iPSCs Banking9.2 Reprogramming methods used in iPSC Banking9.3 Workflow in iPSC Banks9.4 Existing iPSC Banks

10. BIOMEDICAL APPLICATIONS OF iPSCS10.1 iPSCs in Basic Research10.2 iPSCs in Drug Discovery10.3 iPSCs in Toxicology Studies10.4 iPSCs in Disease Modeling10.5 iPSCs within Cell-Based Therapies

11. OTHER NOVEL APPLICATIONS OF iPSCS11.1 iPSCs in Tissue Engineering11.2 iPSCs in Animal Conservation11.3 iPSCs and Cultured Meat

12. DEAL-MAKING WITHIN THE iPSC SECTOR12.1 License Agreement between FUJIFILM Cellular Dynamics and Sana12.2 Century Therapeutics Closes $160 Million Series C Financing12.3 Bluerock Gains Access to Ncardia's iPSCs-derived Cardiomyocytes12.4 Fate Therapeutics' Deal with Janssen Biotech12.5 Century Therapeutics Acquires Empirica Therapeutics12.6 $250 Million Raised by Century Theraputics12.7 BlueRock Therapeutics Launched with $225 Million12.8 Collaboration between Allogene Therapeutics and Notch Therapeutics12.9 Acquisition of Semma Therapeutics by Vertex Therapeutics12.10 Evotec's Extended Collaboration with BMS12.11 Licensing Agreement between Allele Biotechnology and Astellas12.12 Codevelopment Agreement between Allele & SCM Lifesciences12.13 Fate Therapeutics Signs $100 Million Deal with Janssen12.14 Allele's Deal with Alpine Biotherapeutics12.15 Editas and BlueRock's Development Agreement

13. MARKET OVERVIEW13.1 Global Market for iPSCs by Geography13.2 Global Market for iPSCs by Technology13.3 Global Market for iPSCs by Biomedical Application13.4 Global Market for iPSCs by Cell Types3.5 Market Drivers13.6 Market Restraints

14. COMPANY PROFILES

For more information about this report visit https://www.researchandmarkets.com/r/u155vh

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See more here:

Global Induced Pluripotent Stem Cell (iPS Cell) Market Report 2021: In Total, At Least 68 Distinct Market Competitors Now Offer Various Types of iPSC...

Read more
Synthego Launches The Eclipse Platform to Accelerate Research and Development of Next-generation Medicines – PRNewswire

MENLO PARK, Calif., April 7, 2021 /PRNewswire/ --Synthego, the genome engineering company, today announced the launch of Eclipse, a new high-throughput cell engineering platform designed to accelerate drug discovery and validation by providing highly predictable CRISPR-engineered cells at scale through the integration of engineering, bioinformatics, and proprietary science. The launch of this unique CRISPR-based platform is driving the company's growing impact in biopharma R&D, reinforcing Synthego's position as the genome engineering leader.

CRISPR-engineered cells have a wide range of applications in research and development across disease areas, including in neuroscience and oncology. Synthego created theEclipse platformto enhance disease modeling, drug target identification and validation, and accelerate cell therapy manufacturing.

"By industrializing cell engineering, Synthego's Eclipse platform will enable economies of scale, turning a historically complex process into one that is flexible, reliable, and affordable," said Bill Skarnes, Ph.D., professor and director of Cellular Engineering at The Jackson Laboratory and Synthego advisory board member. "Offering CRISPR edits at scale, similar to what Synthego did with sgRNA reagents, puts researchers on the cusp of being able to study thousands of genes, and examine hundreds of variants of those genes. This will allow scientists to more faithfully model the complexity of a human disease, which could lead to the development of therapeutic drugs or next-generation gene therapies for many serious diseases."

To ensure the success of any type of edit, Eclipse uses machine learning to apply experience from several hundred thousand genome edits across hundreds of cell types. With this machine learning, combined with automation, the new platform can reduce costs and increase the scalability of engineered cell production. The Eclipse platform is modular in design, allowing for fast deployment of upgrades or add-ons. It is engineered to use a cell-type agnostic process and immediately benefit researchers working with induced pluripotent stem (iPS) cells and immortalized cell lines.

"We are living in a new era of life sciences innovation one that has added to DNA sequencing and being able to read out of biology, now being able to write into and engineer biology. We created our Eclipse platform at the convergence of science and technology to make genome editing more precise, scalable, and accessible,"said Paul Dabrowski, CEO and co-founder of Synthego. "We are excited to expand our impact on advancing the life sciences innovation with the launch of this unique CRISPR-based platform."

For further information about Eclipse, visit https://www.synthego.com/platforms/eclipse.

About SynthegoSynthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company's platforms vertically integrate proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation enabling the next generation of medicines by delivering genome editing at an unprecedented scale.

SOURCE Synthego

https://www.synthego.com

Continued here:

Synthego Launches The Eclipse Platform to Accelerate Research and Development of Next-generation Medicines - PRNewswire

Read more
NCRAD: Increasing infrastructure for Alzheimer’s disease researchers | National Institute on Aging – National Institute on Aging

The research community understands that progress toward the goal of treatment for Alzheimers disease and related dementias (AD/ADRD) by 2025 is often incremental. But for people with these diseases and their loved ones, time is of the essence. The National Centralized Repository for Alzheimers Disease and Related Dementias (NCRAD) is an NIA-supported resource to help scientists accelerate and streamline their efforts. NCRAD has grown significantly since we last blogged about it, so we wanted to highlight its latest offerings that could make a big difference in your teams future investigations.

First funded in 1990, NCRAD is now one of the largest biorepositories in the field. It serves AD/ADRD scientists by banking a wide range of biospecimens, including samples from more than 93,000 participants and 45 NIA-supported studies. Sample types at NCRAD include DNA, RNA, plasma, serum, lymphoblastoid cell lines, peripheral blood mononuclear cells, fibroblasts, induced pluripotent stem cells, cerebrospinal fluid, brain tissue, and stool. Thanks to recent increases in AD/ADRD research funding, NCRAD already has more than 1 million samples!

Studies banking with NCRAD utilize standard protocols that are clearly delineated and readily available to studies and sites collecting samples. To ensure uniform sample collection, NCRAD establishes procedures and provides training via webinars that are recorded and available on the NCRAD website. NCRAD also provides research teams with kits that include all the needed materials for collecting samples and shipping them back to NCRAD.

A new NCRAD-banked resource is induced pluripotent stem cells (iPSCs). Investigators deposit iPSCs derived from participants with AD/ADRD as well as from healthy controls. NCRADs quality control measures and standardized culture conditions help minimize the great variability found in contributed iPSC lines. Main NCRAD goals are to ease the distribution burden for investigators and to provide standardized, high-quality iPSCs to the research community.

Through a collaboration with NIAGADS (the NIA Genetics of Alzheimers Disease Data Storage Site), NCRAD supports state-of-the-art genome and genotyping arrays for samples in several new studies. These studies include the 90+ Study, a longitudinal study of aging and cognition of participants over age 90, and the ANGI (Amyloid Neuroimaging and Genetics Initiative) Study, an add-on for participants in the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study. The ANGI study paired DNA with the clinical and imaging data collected in the IDEAS Study. The genome-wide association study (GWAS) data for both these studies are available through NIAGADS.

The NCRAD website features webinars about the process for requesting samples and its online 90+ Study and ANGI catalog systems. To learn more, email alzstudy@iu.edu and follow @NCRAD_AD on Twitter.

Editors Note: This post details a significant data sharing resource for NIA supported scientists. Learn more about forthcoming NIA and NIH requirements on data sharing for all applicants and grantees.

Visit link:

NCRAD: Increasing infrastructure for Alzheimer's disease researchers | National Institute on Aging - National Institute on Aging

Read more